Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart transplantation: current status.

J G Copeland1, L J Rosado, G Sethi

  • 1Department of Surgery, University of Arizona Health Sciences Center, Tucson.

Clinical Transplants
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing <i>Mycoplasma genitalium</i> testing across a London-based sexual health service: A quality improvement project.

International journal of STD & AIDS·2020
Same author

Concomitant back pain as a predictor of outcome after single level lumbar micro-decompressive surgery - A study of 995 patients.

Journal of orthopaedics·2019
Same author

Gamma Radiation-Induced Disruption of Cellular Junctions in HUVECs Is Mediated through Affecting MAPK/NF-<i>κ</i>B Inflammatory Pathways.

Oxidative medicine and cellular longevity·2019
Same author

Corrigendum to "Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics" [Drug Discov. Today 22 (December (12)) (2017) 1765-1781].

Drug discovery today·2018
Same author

Influenza A virus enhances its propagation through the modulation of Annexin-A1 dependent endosomal trafficking and apoptosis.

Cell death and differentiation·2016
Same author

Occurrence and impact of domestic violence and abuse in gay and bisexual men: A cross sectional survey.

International journal of STD & AIDS·2016
Same journal

Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.

Clinical transplants·2017
Same journal

Influenza Immunization and the Generation of Anti-HLA and Anti-MICA Antibodies in Patients with Renal Failure and in Kidney Transplant Recipients.

Clinical transplants·2017
Same journal

From Accurate Assessment of Anti-HLA Antibody MFI to Complement-Binding Assays.

Clinical transplants·2017
Same journal

Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.

Clinical transplants·2017
Same journal

Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD).

Clinical transplants·2017
Same journal

C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.

Clinical transplants·2017
See all related articles

Current triple therapy for transplant patients doubles survival half-life to 15 years, outperforming older treatments. Long-term risks include infection, graft arteriosclerosis, and malignancy, despite reduced rejection rates.

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation Medicine

Background:

  • Historical immunosuppressive therapies have limitations in long-term transplant patient survival.
  • Optimizing immunosuppression is crucial for improving graft longevity and patient outcomes.
  • Understanding post-transplant complications is key to enhancing survival rates.

Purpose of the Study:

  • To evaluate the long-term efficacy of a current triple therapy regimen in kidney transplant recipients.
  • To compare the survival outcomes of current triple therapy with historical treatment protocols.
  • To identify the primary threats to long-term graft and patient survival post-transplantation.

Main Methods:

  • Retrospective review of 293 kidney transplant patients.
  • Analysis of survival curves comparing different immunosuppressive strategies.

Related Experiment Videos

  • Assessment of complication incidence, including rejection, infection, and malignancy.

    • Main Results:

    • Current triple therapy demonstrated a 15-year half-life, twice that of conventional or cyclosporine (CsA) and prednisone (P) therapy.
    • Graft rejection was significantly reduced after the initial 1-3 months post-transplantation with current therapy.
    • Annual incidence of infection remained approximately 10%, posing a continued threat.

    Conclusions:

    • The current triple therapy regimen significantly improves long-term transplant survival compared to older methods.
    • While acute rejection is mitigated, infection remains a persistent challenge for transplant recipients.
    • Graft arteriosclerosis, infection, and malignancy are the principal factors impacting long-term survival in this patient cohort.